India-based pharmaceutical giant Dr. Reddy's Laboratories has announced the launch of its generic Semaglutide Injection in Canada, becoming one of the first companies to introduce the product in the Canadian market following approval from Health Canada.
The company received the Notice of Compliance (NOC) from Health Canada on April 28, 2026, paving the way for commercial launch within weeks. Canada has also become the first G7 nation to grant market authorization for generic Semaglutide Injection, highlighting a significant development in the global diabetes treatment market.
Semaglutide is widely used for the treatment of type 2 diabetes and belongs to the GLP-1 receptor agonist class, a rapidly growing segment in the pharmaceutical industry due to increasing demand for advanced diabetes and obesity therapies.
According to the company, the generic Semaglutide Injection will be available in pre-filled pen formats with strengths of 2 mg/pen and 4 mg/pen. The once-weekly injectable therapy is intended to improve glycemic control in adults with type 2 diabetes when used alongside diet and exercise.
Erez Israeli, Chief Executive Officer of Dr. Reddy's Laboratories, said the launch demonstrates the company’s strong capabilities in complex drug and peptide development. He added that the Canada rollout follows the recent Indian launch of the company’s semaglutide brand “Obeda®,” and reflects its strategy to expand access to GLP-1 therapies across international markets.
The development is expected to strengthen Dr. Reddy’s position in the global diabetes care segment, especially as demand for GLP-1 based medicines continues to rise worldwide.
Headquartered in Hyderabad, Dr. Reddy's Laboratories is one of India’s leading pharmaceutical companies with operations across the USA, Europe, Russia, China, Brazil, and other international markets.
